Clinical, translational and multidisciplinary research

  • ReSScue: Aiming to reduce disease-related gastro-intestinal symptoms in systemic sclerosis (SSc) by repeat intestinal infusions of Anaerobic Cultivated Human Intestinal Microbiome (ACHIM); a Phase II, randomized, double-blinded placebo-controlled 20 week multicentre study. Included 67 patients, ongoing preclinical analyses of biosamples.
  • Investigator-initiated study: Risk stratification, treatment regimens, and outcomes in systemic sclerosis–associated pulmonary arterial hypertension
  • ILD in CTDs: Prospective cohort study of ILD in CTDs and RA to assess disease progression.
  • Lung imaging: Detection and testing of novel imaging techniques for ILD in fibrotic inflammatory rheumatic diseases.
  • NorG4: The Norwegian IgG4-related disease project. A nationwide population-based cohort study of IgG4-related disease.
  • OptimiSSce: Optimizing pulmonary arterial hypertension (PAH) management in systemic sclerosis (SSc).
  • Molecular profiling of lung tissue in CTD-ILD in collaboration with UCLA and Zurich (USZ)
  • The Oslo university hospital (OUH) Strategic Research area- Novel personalized management strategies for fibrosing diseases 2022- 2027 with Anna-Maria Hoffmann-Vold as Project leader. Collaboration with Convergence environments= UIO strategic research area (Fibro-PET) with Mona-Elisabeth Rootwelt-Revheim as leader. The overall purpose of the environment is to develop personalized management strategies including early identification, treatment, monitoring, patient dialogue and outcome assessment in patients with fibrosing diseases.
  • Stem cell transplant: HMAS in Norway and EUSTAR
 
Scroll to top